Core Viewpoint - The company, Xianju Pharmaceutical (002332.SZ), announced its participation in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, indicating a strategic move to secure market presence and enhance sales for its product, Vecuronium Bromide injection [1] Group 1 - The company will participate in the bidding process from October 27 to October 28, 2025 [1] - The product, Vecuronium Bromide injection, is intended for use as an adjunct in general anesthesia, specifically for tracheal intubation and muscle relaxation during surgery [1] - The company aims to have its product selected in this centralized procurement, which could lead to increased market access and sales opportunities [1]

Core Viewpoint - The company, Xianju Pharmaceutical, announced its participation in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, with its product, Vecuronium Bromide Injection, expected to be selected for this procurement [1] Group 1 - The procurement event is scheduled from October 27 to October 28, 2025 [1] - The product Vecuronium Bromide is primarily used as an adjunct in general anesthesia for tracheal intubation and muscle relaxation during surgery [1]

Core Viewpoint - The company participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement from October 27 to October 28, 2025, with its product, injection vecuronium bromide, expected to be selected in this procurement [1] Financial Performance - The sales revenue of injection vecuronium bromide for the year 2024 is projected to be 17.6915 million yuan, accounting for 0.44% of the company's total revenue for 2024 [1] - For the period from January to September 2025, the sales revenue reached 14.1840 million yuan, representing 0.50% of the company's total revenue for the same period [1]

证券代码：002332 证券简称：仙琚制药 公告编号：2025-048 浙江仙琚制药股份有限公司 关于公司产品拟中选第十一批全国药品集中采购的公告 2、按照相关规定，采购周期内采购协议每年一签。续签采购协议时，约定采购量原则上不少于各地该 中选药品上年约定采购量。 二、本次产品拟中选对公司的影响 公司上述拟中选的注射用维库溴铵2024年度及2025年1-9月销售收入情况如 下： 1 药品 名称 适应症 剂型 /规 格 拟中选 价格 （元/瓶） 拟主供 省市 采购周期 注射用 维库溴 铵 主要作为全麻辅 助用药，用于全麻 时的气管插管及 手术中的肌肉松 弛。 粉针剂/4mg 2.24 江苏 浙江 陕西 吉林 黑龙江 辽宁 自中选结 果执行之 日起至 2028年12 月31日 一、 拟中选产品基本情况 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）于2025年10月27日至10 月28日参加了国家组织药品联合采购办公室（以下简称"联采办"）组织的第十 一批全国药品集中采购的投标工作。公司产品注射用维库溴铵拟中选本次集中 ...

Financial Performance - Cumulative revenue for the first three quarters of 2025 is 2.826 billion, a decrease of 12.71% compared to the same period last year [2] - Single-quarter revenue for Q3 2025 is 956 million, down 13% year-on-year from 1.099 billion [3] - Cumulative net profit after deducting non-recurring items is 363 million, a decline of 30.3% from 521 million in the previous year [3] - Single-quarter net profit for Q3 2025 is 96 million, down approximately 21% from 123 million in Q2 2025 [3] - Gross margin for the first three quarters is approximately 62.3%, up from 54.6% in the same period last year [3] Asset and Liability Overview - Total assets as of the end of Q3 2025 are 7.263 billion, with net assets of 6.025 billion [3] - Asset-liability ratio is approximately 17.04% [3] Sales and Profit Decline Analysis - Sales revenue decline is attributed to factors such as centralized procurement, price fluctuations in raw materials, and intensified market competition [3] - Prices of raw materials have shown a downward trend, affecting both revenue and profit margins [3] - The company aims to enhance production efficiency and innovate to adapt to the changing market landscape [3] Sales Expense Increase - Increase in sales expenses is primarily due to the market introduction phase of several new products [4] - The company is preparing a professional sales team to support the commercialization of new products [4] R&D Strategy - The company has completed the consistency evaluation of existing products and is actively exploring new targets based on clinical needs [5] - Focus on innovative development, including steroid-based innovations and exploring new attractive products beyond steroid limitations [5] Export Situation - The company's export of formulation products is in its early stages, with limited sales primarily in the U.S. market [6] - The company is strategically planning its export products based on various factors including market demand and entry barriers [6] Market Performance by Product Category - Gynecological products generated 310 million in sales, down from 340 million last year, with a notable decrease in sales of progesterone capsules [7] - Respiratory products achieved 600 million in sales, a 15% increase year-on-year, while sales of tiotropium bromide inhalation powder declined by 32% [8] Company Collaboration - Italian Newchem company reported stable revenue of approximately 434 million in the first quarter, maintaining collaboration with Xianju [9] - The company is enhancing production processes and exploring new markets to support future growth [9] Product Approval Status - The company submitted a New Drug Application for Omecamtiv Mecarbil injection in September 2024, currently in the review process [10]

Core Viewpoint - The company has released its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information disclosed, with no significant omissions or misleading statements [2][10][12]. Financial Data Summary Major Financial Indicators - Prepayments increased by 179.68% compared to the beginning of the year, amounting to an increase of 56.24 million yuan, primarily due to increased contractual prepayments [3]. - Other receivables rose by 31.56%, increasing by 14.47 million yuan, mainly due to an increase in other temporary payments [3]. - Other current assets increased by 46.77%, up by 8.02 million yuan, attributed to an increase in retained tax amounts [3]. Balance Sheet Changes - Short-term borrowings surged by 1422.48%, increasing by 121.05 million yuan, mainly due to increased borrowings during the period [4]. - Notes payable increased by 295.34%, up by 65.93 million yuan, primarily due to increased use of notes payable for settling payments [4]. - Other payables rose by 73.58%, increasing by 134.45 million yuan, mainly due to the impact of payable dividends [4]. - Non-current liabilities due within one year increased by 486.42%, up by 95.65 million yuan, primarily due to an increase in long-term borrowings due within one year [4]. Profit and Loss Statement Changes - Financial expenses increased by 77.46% compared to the same period last year, rising by 18.07 million yuan, mainly due to reduced interest income [5]. - Investment income decreased by 196.07%, down by 25.00 million yuan, primarily due to the disposal of equity in the previous period [5]. - Asset disposal income increased by 6432.33%, up by 47.00 million yuan, attributed to asset transfers during the period [5]. Cash Flow Statement Changes - Tax refunds received increased by 236.45%, up by 3.05 million yuan, mainly due to increased export tax rebates [6]. - Cash paid for purchasing goods and services decreased by 39.07%, down by 335.90 million yuan, primarily due to reduced cash payments for purchases [6]. - Cash received from borrowings increased by 6480%, up by 324.00 million yuan, mainly due to increased borrowings during the period [6]. Shareholder Information - The total number of shareholders and the situation of the top ten shareholders have been reported, with no significant changes noted [7].

证券代码：002332 证券简称：仙琚制药 公告编号：2025-047 浙江仙琚制药股份有限公司 第八届监事会第十二次会议决议公告 会议以 7 票同意，0 票弃权，0 票反对，审议通过了《公司 2025 年第三季度 报告》。经审核，监事会认为：公司董事会编制和审核《公司 2025 年第三季度报 告》程序符合法律、行政法规和中国证监会的规定；报告内容真实、准确、完整 地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 特此公告。 浙江仙琚制药股份有限公司 监事会 2025 年 10 月 28 日 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）第八届监事会第十二次会 议通知已于2025年10月16日以电子邮件方式向公司全体监事发出，会议于2025 年 10 月 27 日上午以通讯方式召开。本次会议应参加监事 7 名，实际参加监事 7 名，会议由公司监事会主席吴天飞先生召集并主持。本次会议的召集、召开符合 《中华人民共和国公司法》和《公司章程》的有关规定。全体与会监事以记名投 票方式通过以下决议： ...

第八届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002332 证券简称：仙琚制药 公告编号：2025-046 浙江仙琚制药股份有限公司 特此公告。 浙江仙琚制药股份有限公司 董事会 2025 年 10 月 28 日 浙江仙琚制药股份有限公司（以下简称"公司"）第八届董事会第十七次会 议通知已于2025年10月16日以电子邮件方式向公司全体董事发出，会议于2025 年 10 月 27 日上午以通讯方式召开。本次会议应参加董事 9 名，实际参加董事 9 名，会议由公司董事长张宇松先生召集并主持。本次会议的召集、召开符合《中 华人民共和国公司法》和《公司章程》的有关规定。全体与会董事以记名投票方 式通过以下决议： 会议以 9 票同意，0 票弃权，0 票反对，审议通过了《公司 2025 年第三季度 报告》。 ...

浙江仙琚制药股份有限公司 2025 年第三季度报告 证券代码：002332 证券简称：仙琚制药 公告编号：2025-045 浙江仙琚制药股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 浙江仙琚制药股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 减 | 年同期增减 | | | 营业收入（元） | 956,353,361.96 | -12.99 ...

Core Viewpoint - The report by Zhiyan Consulting highlights the growth and future trends in China's chemical pharmaceutical industry, indicating a steady increase in production and market dynamics from 2025 to 2031 [1]. Industry Summary - According to the National Bureau of Statistics, the production of chemical pharmaceutical raw materials in China reached 263,000 tons in August 2025, with a cumulative production of 2,477,000 tons from January to August 2025, reflecting a growth of 3.1% [1]. - The report provides insights into the supply and demand situation in the chemical pharmaceutical industry, projecting future trends and market conditions [1]. Company Summary - Listed companies in the report include Heng Rui Medicine, East China Medicine, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical, indicating a diverse range of players in the market [1]. - The report emphasizes the importance of industry research and consulting services in aiding investment decisions, showcasing Zhiyan Consulting's expertise in providing comprehensive industry solutions [1].